The FDA to Review Diabetes Drugs for Additional Benefits
On June 28th an advisory panel to the U.S. Food and Drug Administration (FDA) will vote on whether a diabetes drug cuts the risk of cardiovascular death and whether or not the company can include this on the drugs label. Read article here…..
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.